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A B S T R A C T
Background
Male pseudohermaphroditism, or Leydig cell hypoplasia (LCH), is an autosomal recessive
disorder in individuals with a 46,XY karyotype, characterized by a predominantly female
phenotype, a blind-ending vagina, absence of breast development, primary amenorrhea, and
the presence of testicular structures. It is caused by mutations in the luteinizing hormone/
chorionic gonadotropin receptor gene (LHCGR), which impair either LH/CG binding or signal
transduction. However, molecular analysis has revealed that the LHCGR is apparently normal in
about 50% of patients with the full clinical phenotype of LCH. We therefore searched the
LHCGR for novel genomic elements causative for LCH.
Methods and Findings
In the present study we have identified a novel, primate-specific bona fide exon (exon 6A)
within the LHCGR gene. It displays composite characteristics of an internal/terminal exon and
possesses stop codons triggering nonsense-mediated mRNA decay (NMD) in LHCGR.
Transcripts including exon 6A are physiologically highly expressed in human testes and
granulosa cells, and result in an intracellular, truncated LHCGR protein of 209 amino acids. We
sequenced exon 6A in 16 patients with unexplained LCH and detected mutations in three
patients. Functional studies revealed a dramatic increase in the expression of the mutated
internal exon 6A transcripts, indicating aberrant NMD. These altered ratios of LHCGR transcripts
result in the generation of predominantly nonfunctional LHCGR isoforms, thereby preventing
proper expression and functioning.
Conclusions
The identification and characterization of this novel exon not only identifies a new regulatory
element within the genomic organization of LHCGR, but also points toward a complex network
of receptor regulation, including events at the transcriptional level. These findings add to the
molecular diagnostic tools for LCH and extend our understanding of the endocrine regulation
of sexual differentiation.
The Editors’ Summary of this article follows the references.
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Introduction
The gonadotropic hormones luteinizing hormone (LH) and
chorionic gonadotropin (CG) play an essential role in male
sexual differentiation. The action of both hormones is
mediated by the LH/CG receptor (LHCGR), a G protein-
coupled receptor, expressed in Leydig, granulosa-lutein, and
theca cells. The human LHCGR gene (NCBI GeneID 3973;
http://www.ncbi.nlm.nih.gov/) consists of 11 exons and ten
introns, and spans 67 kbp on Chromosome 2 p21. Ten of the
11 exons encode the extracellular domain, while exon 11
encodes the seven-transmembrane and intracellular domains
[1]. Several inactivating LHCGR mutations have been
described in patients with 46,XY disorder of sex development
(46,XY DSD) due to Leydig cell hypoplasia (LCH), an
autosomal recessive disorder characterized by a predomi-
nantly female phenotype with a blind-ending vagina, absence
of breast development, and primary amenorrhea and the
presence of testicular structures [2]. However, in a substantial
number of patients (50%) with the classical symptoms of
LCH, no mutations of the LHCGR are found (unpublished
data) [3,4]. This finding raises the hypothesis that genomic
defects in other genes or in LHCGR regions not considered so
far may cause LCH. In this study we therefore searched the
LHCGR gene for novel genomic elements in which genetic
alterations could lead to LCH.
Methods
Study Participants
Patients. Sixteen patients with complete LH resistance (male
pseudohermaphroditism) due to LCH type 1 gave written
informed consent to participate in the study. All patients had
karyotype 46,XY, a blind-ending vagina, no breast develop-
ment, and testicular structures in the abdomen and displayed
the full phenotype of LCH [4]. All patients had been previously
screened for LHCGRmutations and found to be negative.
The patients in this manuscript have given written
informed consent (as outlined in the PLoS publication
consent form, http://journals.plos.org/plos_consent_form.
pdf) to publication of their case details.
Control group. Forty-one fertile men with normal LH and
testosterone levels and normal spermatogenesis were in-
cluded as a control group. The institutional review board
approved the study and written informed consent was
obtained from each participant.
Case reports. A 20-year-old Turkish woman was referred to
the gynecologist because of primary amenorrhea. She was the
first daughter of a sibship of three children from consangui-
neous parents. She presented with a lack of breast develop-
ment, normal pubic and axillary hair, blind-ending vagina (4
cm), and normal labia majora and minora. No clitoris
hypertrophy was seen. She was obese (122 kg, 173 cm). Testes
were palpable in the inguinal regions, but no mu¨llerian
derivatives were found by ultrasound. Karyotyping was
performed and revealed a 46,XY karyotype. Hormone
analysis showed very low serum testosterone levels (0.1
nmol/l), which could be not stimulated by treatment with
7,500 IU of hCG (maximal testosterone levels, 0.1 nmol/l).
Serum levels of LH and FSH were elevated (LH 15.8 IU/l, FSH
13.6 IU/l) and responsive to stimulation with 100 lg of GnRH
(LH 69.8 IU/l, FSH 20.1 IU/l).
At the age of 26 y her sister, younger by 6 y, was referred to
the Department of Endocrinology of the University of Essen
also because of primary amenorrhea. She presented with the
same phenotype as her older sister: 46,XY karyotype, blind-
ending vagina (6 cm), inguinal gonads, obesity (126 kg, 176
cm), low estradiol level (21 pg/ml), low testosterone level (0.06
nmol/l, increasing to 1.9 nmol/l after 7,500 IU of hCG),
elevated gonadotropin level (LH 24.3 IU/l, FSH 20.1 IU/l)
responsive to 100 lg of GnRH (LH 98.0 IU/l, FSH 29.6 IU/l).
Gonadectomy was performed and histological evaluation
revealed complete Sertoli cell–only syndrome with thickened
tubule walls and focally disorganized tubules. Leydig cells
appeared immature and their number was not evidently
changed when compared to normal testes. In both affected
sisters the previously performed genetic analysis of the
LHCGR gene did not give any hint of mutations or other
genetic alterations in other candidate genes.
A third patient was analyzed for mutations in the LHCGR
gene at the age of 21 mo. She was born to unrelated parents
and presented a female phenotype with labial synechia.
Gonads were palpable in both labia majora and a karyotype
46,XY was found. Postnatal testosterone levels were low and
the girl was gonadectomized at the age of 2 mo. Histology
showed fibrotic testis tissue. A heterozygous mutation leading
to a Thr461Ile substitution in exon 11 of the LHCGR gene,
resulting in complete inactivation, was found.
Cells and Tissues
Human testis tissues were obtained from patients under-
going orchidectomy because of prostate cancer, and gran-
ulosa cells were obtained from women undergoing assisted
reproduction. Written informed consent was obtained from
the patients to use their material for scientific research. In
addition, human adrenal and testis RNA was purchased from
a commercial source (Biocat, Heidelberg, Germany).
Snap-frozen testes were obtained from different primate
species within the framework of a project on efficacy of
spermatogenesis funded by the German Research Foundation
(WE1167/4–1/2). Tissue from the cynomolgus monkey (Macaca
fascicularis) was obtained from our own primate colonies at
the Institute of Reproductive Medicine (Muenster, Germany).
All experiments were conducted according to the German
Law on Animal Care and Experimentation. The cynomolgus
monkey testis cDNA library has been described before [5].
Genomic DNA and RNA Isolation
Genomic DNA was isolated from EDTA-treated blood
samples using the Flexigene DNA isolation kit (Hilden,
Germany). RNA was isolated using UltraSpec (Biotecx,
Houston, Texas, United States).
Exon Trap Experiments
Analysis of exon 6A was performed using the exon trapping
system (Invitrogen, Karlsruhe, Germany). Plasmid constructs
were generated by amplification of a DNA fragment from
human genomic DNA using the specific primers Ex6a 150 fw
(forward) 59-CGCTCGAGCCTGCCCTCCTCGGCCTCC-
CAAAG-39 and LHCGR Ex6a 150 rev (reverse) 59-
CGCGGATCCCTTTATAAGCAGCCGGTAGAGCTG-39 con-
taining the restriction site Xho1 within the forward primer or
BamH1 for the reverse primer. The fragment was amplified
using the following thermocycler conditions: 94 8C for 50 s,
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64 8C for 50 s, 72 8C for 90 s for 35 cycles. The obtained amplicon
was restricted by Xho1 and BamH1 and cloned into the
pSPL3 vector. Sequence fidelity was confirmed by DNA
sequencing.
Transient Transfection and Reverse Transcription PCR
COS7 cells were seeded on petri dishes and cultured to
40%–50% confluency. 12 lg of plasmid DNA per dish was
used for transfection by Lipofectamine (Invitrogen, 12 ll/
dish). 6 h later the transfection was stopped by adding DMEM
supplemented with 20% FCS. 48 h later the cells were lysed
using UltraSpec and RNA isolated according to the manu-
facturer’s protocol. Reverse transcription was performed
using the vector-specific primers SA2 59-TCTGAGTCACCTG-
GACAACC-39 and exon 6A rev (reverse) 59-GTAACATGA-
CAATTATACATG-39, or b-actin reverse primer as a control
for RNA integrity. Subsequent PCR was performed with the
primer combination SD6 59-ATCTCAGTGGTATTTGT-
GAGC-39 and SA2 (see above), or SD6/exon 6A rev (reverse)
and b-actin for/rev (forward/reverse) using the following
thermocycler conditions: 94 8C for 50 s, 60 8C for 50 s, 72 8C
for 90 s for 35 cycles. The PCR reactions were subjected to 2%
agarose gel electrophoresis and documented using the Multi-
Image Light system (Biozym, Oldendorf, Germany). In func-
tional experiments, COS7 cells were stimulated 24 h after
transfection by hCG (Choragon, Ferring GmbH, Kiel Ger-
many) dissolved in DMEM. Extracellular cAMP concentrations
were determined 3 h after stimulation in media by radio-
immunoassay.
In Vitro Mutagenesis
Mutations were introduced using the Quick Change site-
directed mutagenesis kit from Stratagene (Heidelberg, Ger-
many). Sequence fidelity was confirmed by DNA sequencing.
Real-Time Quantitative PCR for the Relative Gene
Expression of LHCGR Variants
The commer c i a l l y a v a i l a b l e TaqMan a s s a y
#HS20896337_m1 (LHCGR; Applied Biosystems, Darmstadt,
Germany) was used to detect the known LHCGR transcripts
(without exon 6A). For the relative quantification of the
LHCGR terminal exon 6A and internal exon 6A variants,
specifically designed assays were used. The terminal exon 6A
assay is directed toward the 39 region of exon 6A, while the
internal exon 6A variants are detected by an assay spanning
the 59 region of exon 6A to exon 7 of the LHCGR gene. The
primers and probes of the assays designed ad hoc are listed
below.




LHCGR internal exon 6A short. Forward primer, 59-
CTCTGAAATGAAGAGATAGATGTGAAGCA-39; reverse
primer, 59-GCATGACTTTGTACTTCTTCAAATCCAT-39;
TaqMan MGB FAM-labeled probe, 59-TTCCATATAGTTTG-
CAATTTT-39.
LHCGR internal exon 6A long. Forward primer, 59-
CAGAGGACTCTCTTTTATATCACTGGATTC-39; reverse
primer, 59-TGACTTTGTACTTCTTCAAATCCATTTCCA-39;
TaqMan MGB Fam-labeled probe, 59-ACTGCCTTTGTATAG-
TACTTTTA-39.
LHCGR exon 6/7 without exon 6A. Forward primer, 59-
ACCACCATACCAGGAAATGCTTTT-39; reverse primer, 59-
AAAGATTCAGTGTCGTCCCATTGA-39 (AAAGAT corre-
spond to vector sequence); TaqMan MGB Fam-labeled probe,
59-CAAGGGATGAATAATGAATCTGT-39
Assays. Reverse transcription of 2 lg of total RNA/tissue
was performed using random hexamer primers and Super-
script II enzyme according to the manufacturer’s protocol
(Invitrogen).
TaqMan PCR was performed using the following amplifi-
cation profile: an initial step consisting of 50 8C for 2 min and
95 8C for 10 min followed by 40 cycles at 95 8C for 15 s and 60
8C for 1 min. PCR efficiency was verified with different cDNA
concentrations yielding linear amplification. For the detec-
tion of the LHCGR variants 200 ng of cDNA per reaction were
used.
The relative quantification of gene expression was analyzed
according to Livak et al. [6] using the 2DDCT method.
Normalization of RNA content was performed using 18S
TaqMan gene expression assay (Hs # 99999901; Applied
Biosystems). The mRNA levels of the known LHCGR (without
exon 6A) in the testis tissue were used to calibrate by relative
quantification the expression levels of the other transcripts.
LHCGR Minigene Constructs
The genomic region encompassing exon 6, exon 6A, and
exon 7, with a total length of 9,534 bp, was amplified from
genomic DNA of one patient with the A557C mutation and
one male individual lacking the mutation using the Expand
Long PCR kit by Roche (Mannheim, Germany). The following
two primers and manufacturer-recommended thermocycler
conditions were used: exon 6 for (forward) 59-GTGATAACT-
TACACATAACCACCATACCAGG-39 and exon 7 rev (re-
verse) 59-GTCAGTGTCGTCCCATTGAATGCATGAC-39).
The obtained amplicons were cloned into the pTarget
expression plasmid (Promega, Germany) and sequence fidel-
ity was confirmed by DNA sequencing.
These constructs were further modified for signal trans-
duction studies. To mimic the in vivo situation as close as
possible we engineered a construct consisting of LHCGR
cDNA and embedding the genomic intron 6 with exon 6A. To
reduce the length of the intron to a manageable size the
minigene constructs with the genomic region encompassing
intron 6 from both wild-type and A557C LHCGR were
digested with EcoRV, 6,209 bp were removed from the
intronic region 39 of exon 6A, and the remaining parts were
re-ligated. A functional analysis of the shortened constructs
revealed a similar splicing pattern to the full-length con-
struct. Thereafter, a three-step cloning strategy was em-
ployed. In the first step cDNA from exons 1–6 was amplified
and joined to the 59 end of the shortened minigene construct
by overlapping PCR, yielding a product containing exons 1–6,
shortened intron 6, and exon 7; this product was subsequently
cloned into the pTarget vector. In the second step, the 39 end
of shortened minigene construct was joined to exons 7–11,
yielding a product containing exon 6, shortened intron 6, and
exons 6–11; this product was also cloned into the pTarget
vector. In the third step both constructs were digested with
SacI and a fragment containing exons 1–6 and extending into
the intronic region was used to replace the 59 part of the
construct encoding exon 6, intron 6, and exons 7–11. The
resulting construct consisted of a chimera of partial LHCGR
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cDNAs and intron 6 containing exon 6A. Sequence fidelity
was repeatedly verified by complete DNA sequencing of the
different constructs. Primers used for amplification were as
follows. LHCGR exons 1–6, forward primer 59-ATGAAG-
CAGCGGTTCTCGGCGCTGC-39; reverse primer 59-
GCATTTCCTGGTATGGTGGTTATGTGTAAGTTATCAC-
39. LHCGR exons 7–11, forward primer 59-CAAACTATATG-
GAAATGGATTTGAAGAAG-39; reverse primer 59-TTAA-
CACTCTGTGTAGCGAGTCTTGTC-39.
Northern Blot Hybridization. Northern blots were either
obtained from a commercial source (Human Adult Normal
Tissue, Blot V, Biocat, Heidelberg, Germany,) or made from
adult marmoset tissues (ovary, liver, muscle). Membranes
were hybridized using the FastHyb Solution (BioChain,
Heidelberg, Germany) at 42 8C overnight. As probes either
a fragment containing only exon 6A or a full-length human
LHCGR cDNA (lacking exon 6A) were used. Both probes were
radioactively labeled using a-dCTP32 with specific activity of
. 23 107 cpm/lg DNA. Blots were sequentially hybridized to
the two probes. After hybridization washing was performed
using 0.1 SSC/0.5% SDS at 65 8C. Blots were exposed for 1–6 h
in Phosphorimager cassettes and developed by a Phosphor-
imager (Storm 860, Molecular Dynamics)
Protein Expression of the Full-Length LHCGR and of the
LHCGR Terminal Exon 6A Variant
The protein expression studies of LHCGR exon 6A were
performed using a human HA-tagged, full length LHCGR
cDNA cloned into the pcDPS expression plasmid (kindly
provided by Dr. T. Gudermann, University of Marburg,
Germany). The HA tag is directly located after the LHCGR
signal peptide and can be visualized by immunofluorescence
using a HA-specific antibody (sc 7392, Santa Cruz, California,
United States). The LHCGR exon 6A variant was generated by
a restriction enzyme–based cloning strategy, using Hind III
and Spe1, thereby removing most of the LHCGR cDNA
except the most N-terminal part, which subsequently was
joined to an LHCGR exon 6A variant treated with the same
restriction enzymes beforehand. Both constructs were tran-
siently transfected into COS7 cells and immunofluorescence
was detected by using the HA antibody followed by a
monoclonal IgG2a antibody (Sigma, Deisenhofen, Germany)
and fluorescence was imaged by a Zeiss Axioscope micro-
scope.
Web Resources
Sequence alignments were performed using the ClustalW
program (http://www.ebi.ac.uk/Tools/). Exon splicing binding
sites were identified using the exon splicing enhancer (ESE)
finder software (http://rulai.cshl.edu/tools/ESE/). Other
searches were performed using the toolbox of the Alternative
Splicing Database project (http://www.ebi.ac.uk/asd/). Chim-
panzee LHCGR sequences were extracted from the NCBI
Nucleotide database at http://www.ncbi.nlm.nih.gov/entrez/
viewer.fcgi?list_uids¼114577822.
Results
A Cryptic, Functional Exon in the LHCGR Gene
In our effort to clone LHCGR variants we screened a
cynomolgus testis cDNA library and human granulosa cell
mRNA for LHCGR transcripts, and systematically identified
unusual LHCGR variants consisting of exons 1 to 6 and
additional unknown sequences either terminated by a poly(A)
tail or continuing with exons 7–11 (Figure 1A). A BLAST
search yielded a perfect match to the intronic region between
exon 6 and 7 of the human LHCGR gene (from nucleotide
position 33,900 to 34,200). Inspection revealed the presence
of a 39 splice acceptor site (AG) and a 39 polyadenylation
signal (AATAAA) indicative of a terminal exon [7]. Moreover,
two internal 59 splice sites were evident which, together with
the 39 acceptor site, give rise to a 159 bp (short) or to a 207 bp
(long) internal exon (Figure 1B). Therefore, the human
LHCGR gene contains an additional, previously unrecognized
putative exon within intron 6 that can be spliced into the
novel LHCGR transcripts following two different routes. We
designated this new exon as exon 6A.
Exon trap experiments with the human genomic region
surrounding exon 6A yielded two transcripts including either
159 bp (short) or 207 bp (long) of the internal exon 6A,
indicating specific splicing (Figure 2A, agarose gel lane 1). A
Figure 1. Identification and Characterization of Exon 6A
(A) Upper diagram: Schematic representation of the composite internal/
terminal exon 6A and its location in the LHCGR gene. The asterisk
indicates the translational stop codon. 59 SS indicates the 59 splicing
sites. Middle diagram: Structure of the LHCGR mRNA when exon 6A is
acting as a terminal exon. Lower diagram: Structure of the LHCGR mRNA
when exon 6A is acting as an internal exon.
(B) cDNA nucleotide sequence and putative amino acid sequence of
exon 6A. The three different variants of exon 6A are indicated by the grey
line (internal short and long exon 6A) and black line (terminal exon 6A).
Stop codons are underlined and the polyadenylation signal is boxed. The
39 and 59 splice sites are indicated by small arrows and the position of
the identified mutations by bold arrows. Numbering of nucleotides is
according to the LHCGR mRNA where the translational initiation codon
ATG is considered asþ1 (adenosine).
doi:10.1371/journal.pmed.0050088.g001
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different primer set revealed the expression of the terminal
exon 6A transcript as well (Figure 2B, agarose gel lane 1).
Thus, exon 6A is a novel bona fide composite internal/
terminal exon within the LHCGR gene. However, these
experiments did not give any clues as to the presence of
these exon 6A variants in native tissues. Therefore, using a
different approach we analyzed and quantified the expression
pattern of the known LHCGR mRNA and of the newly
discovered transcripts by real-time reverse transcription PCR
(RT-PCR) in human tissues. As shown in Figure 3, high mRNA
levels including exon 6A were detected in granulosa cells and
in testes, where the terminal variant expression is about five
times higher than that of the known mature mRNA without
exon 6A. In addition, low levels of exon 6A transcripts were
consistently detected in adrenal tissues. mRNA levels for the
two internal exon 6A mRNA variants were significantly lower
than in the known LHCGR without exon 6A (Figure 3).
The genomic region including exon 6A is perfectly
conserved in the chimpanzee as shown by database sequence
comparison. Moreover, we cloned and sequenced the
corresponding genomic region in macaque, marmoset mon-
key, and lemur as representative species of the principal
primate lineages (Figure S1) [8,9]. Exon 6A presumably arose
from a 2.7 kbp insertion, which was found in all primates
investigated in this study. Both the internal and the terminal
exon 6A are highly conserved in these primates, but
comparable sequences are completely lacking in mouse as
well as in other species (Figure S1).
Exon 6A maintains phase 2 splicing typical of the LHCGR
exon organization. However, it contains two stop codons
(Figure 1) and encodes 30 amino acids (pI ¼ 4.5) with no
significant sequence homology to any other known protein
according to FASTA and BLAST searches. The incorporation
of either terminal or internal exon 6A into the transcripts
results in a truncated LHCGR protein of 209 amino acids.
The expression of such protein using a HA-tagged LHCGR-
exon 6A vector in transiently transfected COS7 cells revealed
a predominantly cytosolic localization (Figure S3). The
presence of stop codons qualifies the LHCGR transcript
containing the internal exon 6A as a target for NMD, a
recently described protein-mediated surveillance mechanism
that selectively degrades nonsense mRNAs, thereby regulating
Figure 2. Exon 6A Is a Bona Fide Exon
Exon trap experiments with exon 6A. A genomic fragment of intron 6 of
the human LHCGR gene including exon 6A and 150 bp upstream and
downstream was cloned into the pSPL3 expression vector. COS7 cells
were transiently transfected with this construct and RT-PCR performed.
Primers for the detection of either internal exon 6A (A) or terminal exon
6A (B) are indicated by the arrows. A representative gel electrophoresis is
shown below each expected PCR product. RT-PCR results of COS7 cells
transfected with either the pSPL3 construct containing exon 6A (lane 1)
or empty pSPL3 vector (lane 2) or untransfected COS7 cells (lane 3 in [A])
are shown. The agarose gel photograph in (B) displays the detection of
the spliced terminal exon 6A variant. This splice variant can be obtained
only in the exon trap system, when using a primer combination
employing SD6 and 6A rev (lane 1 in [B]). In addition to the spliced mRNA
variant a second amplicon arose by amplification of a partial fragment of
the pSPL3 vector and the DNA construct covering 150 bp 59 to exon 6A
and exon 6A. The second amplicon, deriving from the DNA construct is
therefore also detectable in a reaction omitting the RT-synthesis (lane 3
in [B]). RNA fidelity was confirmed by the detection of b-actin mRNA.
These results show that exon 6A is recognized as a bona fide exon and is
spliced to give rise to two internal (A) and one terminal variant (B)
mRNAs, as predicted by the primary genomic sequence.
doi:10.1371/journal.pmed.0050088.g002
Figure 3. Tissue-Specific Expression of Exon 6A mRNA
Quantification of LHCGR transcripts in different human tissues by
TaqMan RT-PCR. mRNA extracted from human testes and granulosa
cells and from a commercially available adrenal gland preparation was
analyzed. After normalization against 18S RNA, results were quantified
with the testis transcript without exon 6A as the reference that was
assigned an arbitrary unit (AU) value of 1. Results are shown as mean 6
SEM of three independent experiments. The amplicon without exon 6A
represents the transcript that results in the mature, full-length LHCGR
protein. Transcripts containing the terminal exon 6A are highly expressed
in all tissues analyzed and show a 6-fold higher expression compared to
those without exon 6A in testis and adrenal gland. In comparison, the
expression level of the internal exon 6A transcripts is much lower in
every tissue.
doi:10.1371/journal.pmed.0050088.g003
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protein expression [10]. Elimination of the stop codons by in
vitro mutagenesis significantly increased the efficiency of
internal exon 6A inclusion rate in transiently transfected
COS7 cells (Figure 4). Similar results were obtained when
transfected cells were treated with cycloheximide, a strong
protein synthesis inhibitor, for 4 h (unpublished data). These
results indicate that exon 6A might function as novel
regulator of LHCGR mRNA levels and transcript pattern.
Upon inclusion of the internal exon 6A, an NMD-mediated
process probably results in degradation of the LHCGR
transcript, while inclusion of terminal exon 6A result in an
intracellular, truncated LHCGR protein. Whether the de-
duced truncated 209 amino acid protein occurs naturally in
testis and ovary remains unknown because appropriate
antibodies are not available.
In order to further verify the natural occurrence of mRNA
transcripts including exon 6A, we performed Northern blot
hybridization experiments using specific probes containing
either only exon 6A or the whole LHCGR cDNA without exon
6A (Figure 5). Hybridization of human and marmoset ovarian
mRNA revealed a unique and consistent binding pattern of
the exon 6A probe resulting in a ‘‘comet-like’’ pattern in the
range of 0.5 to 1.4 kb. This finding was specific for the human
and marmoset ovary and was not observed in any other
tissues tested. The comet-like appearance of exon 6A
hybridization in the presence of distinct band patterns
characteristic for the LHCGR mRNA (ranging from 2.3 to
9.5 kb) using the full-length LHCGR cDNA probe, suggests
mRNA degradation, consistent with the hypothesis that the
LHCGR exon 6A internal variants probably undergo NMD.
Mutations of Exon 6A Are Associated with LCH/46,XY DSD
We screened 16 clinically well-characterized patients with
the overt phenotype of LCH and no known mutations in
LHCGR gene for genetic alterations in exon 6A. Three single
nucleotide polymorphisms (SNPs) were identified, for which
the first represents a nonsynonymous SNP at nucleotide
position 599 (starting from exon 1, rs4637137, NCBI-SNP
database, http://www.ncbi.nlm.nih.gov/SNP/) of the LHCGR
changing ATG (Met) into ACG (Thr). The other two SNPs are
located at nucleotide position A653G (rs4490239, SNP data-
base) and at nucleotide position T748G (not found in the SNP
database) within the noncoding region of exon 6A. Determi-
Figure 4. Mutation and Stop Codons Effect Exon 6A mRNA Expression
Analysis of internal exon 6A inclusion in exon trap experiments showing
that removal of the two stop codons (stop) or the presence of the A557C
mutation significantly increases inclusion of the internal exon 6A
variants. Upper image The expression of the terminal and internal
variants was analyzed after transfection in COS7 cells and RT-PCR of
pSPL3 constructs containing the wild-type (WT) exon 6A (along with 150
bp 59 and 39: see Figure 2) or exon 6A after removal of the two stop
codons (stop) or the introduction of the A557C mutation. Lower
histogram: Densitometric quantification (in arbitrary units, AU) of internal
exon 6A variants RT-PCR results (both short and long variant together) of
three or four independent experiments, as indicated in the columns.
Results are expressed as mean 6 SEM. p ¼ 0.0294 (Kruskall-Wallis test).
Results suggest that removal of the stop codons or a mutation in the
SRp55 site reduces NMD of the internal exon 6A transcripts.
doi:10.1371/journal.pmed.0050088.g004
Figure 5. Exon 6A-Specific Transcripts as Detected by Northern Blot
Hybridization
Commercially available Northern blots containing human adult normal
tissues and Northern blots from adult marmoset tissues were sequen-
tially hybridized to an exon 6A probe or the human full-length LHCGR
cDNA.
Lanes 1 and 4, exon 6A probe. Lanes 2 and 5, full-length LHCGR cDNA
probe. Lanes 3 and 6, negative control tissues hybridized either to LHCGR
cDNA (lane 3) or to exon 6A (lane 6). Blots were exposed for 1–6 h using
a Phosphorimager. An RNA marker was used for size determination of
the different transcripts. One Northern blot hybridization out of three
independent experiments is shown. While a range of discrete transcripts
is identified using the full-length LHCGR cDNA probe, a comet-like
hybridization pattern, probably representing degraded mRNA tran-
scripts, is detected by an exon 6A-specific probe. These results indicate
that (i) transcripts containing exon 6A are naturally present in the ovary
and (ii) they undergo massive degradation, possibly by NMD. b-actin
hybridization results are given to demonstrate RNA integrity.
doi:10.1371/journal.pmed.0050088.g005
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nation of the different SNPs in the patient group and in a
cohort of 41 males lacking mutations showed similar
distribution and frequencies. The SNPs T599C and A653G
appear to be in LD (Table S1).
Apart from these SNPs present also in an appropriately
sized control group, we identified three patients from two
families with mutations of exon 6A. In two sisters with LCH
we found a homozygous A to C mutation at position 557
within exon 6A, leading to an amino acid change from Glu
(GAG) to Ala (GCG) (Figure 1B). The two patients were from
consanguineous parents who each carried the same hetero-
zygous mutation, but without any apparent phenotype. An
immunofluorescence-based comparison of the mutated
LHCGR terminal exon 6A protein variant using a HA-tagged
LHCGR and the wild-type LHCGR terminal exon 6A protein
variant yielded no obvious difference; in both cases a
predominantly cytosolic localization was observed (Figure
S3). A heterozygous G to C transversion at position 558 of
exon 6A was found in another patient with LCH from an
independent family who was concomitantly carrier of a
heterozygous inactivating mutation in exon 11 of the LHCGR,
leading to the complete absence of signal transduction upon
stimulation with hCG (Figure S5A). The two mutations were
located on different alleles (compound heterozygosis; Figure
S5B).
According to the ESE finder software, the A557C mutation
strengthens and the G558C mutation abolishes a binding site
for the splicing factor SRp55 (consensus sequence TGCGTC,
mutation sites underlined). We therefore analyzed the effects
of the mutations on the LHCGR transcript pattern in vitro.
Exon trap experiments revealed a 4-fold higher expression
level of the A557C exon 6A (Figure 4) and a 6-fold increase of
the G558C (Figure S5C) internal variants compared to wild
type. The entire LHCGR genomic region from exon 6 to exon
7 from one patient with the A557C exchange and from one
control were cloned and expressed in COS7 cells, and the
transcript pattern quantified by real-time RT-PCR. The
mutation did not induce any change in the expression level
of the transcript without exon 6A (Figure 6). However, the
transcript containing the mutated, terminal exon 6A showed
2.5-fold higher levels compared to the wild type. The long
internal exon 6A variant was about 5-fold more expressed,
whereas for the short internal exon 6A variant the expression
level changed dramatically, with about 3,000-fold increase
compared to the wild type (Figure 6).
In order to assess the functional consequences of the
mutation we conducted signal transduction studies using
constructs consisting of two cDNAs covering exons 1–6 and
7–11 joined by a fragment of intron 6 including exon 6A with
or without the A557C mutation (Figure 7A). Functionality at
the transcriptional level was tested in transiently transfected
COS7 cells. Using primer combinations directed to exon 6
and exon 7 of the LHCGR, RT-PCR yielded a predominantly
expressed amplicon lacking exon 6A (Figure 7B). However,
this pattern was completely reversed when analyzing the
A557C mutation, which resulted in inclusion of both short
and long variants of exon 6A. In functional experiments,
increasing doses of hCG were able to significantly increase
extracellular cAMP concentrations only when the cells were
transfected with the expression vector containing the wild-
type minigene, while response was practically abolished in the
presence of the A557C mutation (Figure 7C). These data
suggest that the mutation in exon 6A specifically alters the
splicing pattern of the LHCGR gene, with a large increase of
transcripts not contributing to the generation of the mature,
full-length receptor protein, and it thereby prevents the
physiological cAMP response to hCG stimulation.
Discussion
We detected a previously unrecognized, functional exon in
the LHCGR gene that is present only in human and other
primates. The appearance of novel exons in the primate
lineage has been described for other receptor genes as well
[11]. For example, a novel 59 exon was identified in the human
tumor necrosis factor receptor gene type 2, which evolved
during evolution from an ALU element to a fully functional
exon present only in apes and humans [12]. Exon 6A was
detected in all primate species analyzed, and we identified an
IMAGE consortium clone from the Old World monkey
Macaca mulatta testis in the EST-NCBI database that, despite
its poor sequence quality, resembles the LHCGR exon 6A
terminal variant. On the other hand, exon 6A-like sequences
are not found in nonprimate species such as rat, mouse, dog,
and fish. Therefore, this novel exon is confined to primates,
where it is highly conserved, indicating strong functional
constraints. We suggest that the genomic organization of the
LHCGR gene in the primates be revised to include exon 6A,
and hypothesize that the mRNA transcript without exon 6A
encoding for the known LHCGR protein represents a splicing
variant of the revised LHCGR gene (Figure S2) [13]. It is
tempting to speculate that the appearance of exon 6A in the
primate LHCGR gene is connected with the evolutionary
appearance of CG in primates and its function during sexual
Figure 6. The A557C Mutation Increases the Expression of the Exon 6A
Short Internal Variant
A 9.5 kb genomic DNA fragment encompassing exon 6 to exon 7 of the
LHCGR gene from one patient carrying the A557C mutation and one
control (wild type) was cloned into the pTarget expression vector and
transiently transfected in COS7 cells. Expression of each variant was
quantified by TaqMan RT-PCR. Results of three independent experiments
(mean 6 SEM) are expressed in arbitrary units (AU) after relative
quantification against the respective wild-type variant, which was
arbitrarily given an AU value of 1.
doi:10.1371/journal.pmed.0050088.g006
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differentiation and in pregnancy recognition and mainte-
nance [9,10].
Northern blot hybridizations revealed a unique pattern for
exon 6A (Figure 5). The strength of the signal obtained with
the exon 6A probe, which is at least comparable with the
signal intensities of the full-length LHCGR mRNA, corrobo-
rates the finding obtained from the relative quantification
studies (Figure 4), while the comet-like signal indicates a
spectrum of transcripts of various lengths. If, as postulated,
exon 6A-containg transcripts undergo NMD this pattern
could derive from partially degraded transcripts from the
LHCGR exon 6A internal variants and from the terminal
exon 6 variant (calculated size approximately 650 bp). A
comparison with transcript patterns from other genes/exons
undergoing NMD is not possible, since to our knowledge no
other data on Northern blot hybridization of such transcripts
have yet been performed.
The exact role of exon 6A is not fully understood yet.
However, this is the first time to our knowledge that a human
disease has been strongly associated with mutations in a
cryptic exon that resembles a target for NMD and does not
contribute to the final/mature protein structure [14]. We
hypothesize that the mutations in exon 6A described in this
paper result in modifications of the relative amounts of each
LHCGR transcript in the Leydig cells, with highly increased
accumulation of variants including exon 6A. This dramatic
change overwhelms the NMD machinery and/or alters the
pattern of protein translation and transportation, resulting
in an insufficient amount of full-length, mature LHCGR
protein at the cell surface. This assumption is corroborated
by the in vitro functional data demonstrating the incapability
of the A557C construct to produce enough functional
receptor protein and by the fact that immunohistological
staining for the LHCGR in testis sections of the A557C
patient was negative, whereas Leydig cells from sections of
intact testes and from LCH patients displaying a ‘‘classical’’
inactivating mutation, hindering proper membrane traffick-
ing or signal transduction of the LHCGR, stained positive
(Figure S4) [15,16].
The phenotype of exon 6A mutations, i.e., LCH and 46,XY
DSD, is illuminating and supportive for a strong regulatory
function of exon 6A. We propose that a complex network,
including the novel transcripts described here and involving
NMD, regulates LHCGR expression at both the transcrip-
tional and translational level (Figure 8). The spectrum of
LHCGR transcripts includes forms with and without exon 6A,
but only the LHCGR mRNA transcript lacking exon 6A will
lead to a functional protein [17]. The levels of such a
‘‘normal’’ transcript and its translation probably depend on
the correct function of two distinct regulatory avenues
processing the LHCGR mRNA including exon 6A. On one
side the variant in which exon 6A acts as terminal exon may
give rise to a protein potentially capable of hormone binding
and/or of interaction with the mature LHCGR protein,
thereby acting as modifier of hormone action. On the other
side the correct processing of the LHCGR transcripts without
exon 6A may depend on the elimination by NMD of the
variants including the internal exon 6A. This complex
pattern of LHCGR transcripts form a network which,
considering the strong physiological constraints of LH/CG
action, must be tightly regulated. We postulate that the strict
regulation of this network is crucial for establishing the
correct ratio between the transcripts, which in turn allows
proper LHCGR functioning [18]. This view is supported by
the fact that the internal and terminal exon 6A transcripts
are physiologically detected along with the ‘‘normal’’ LHCGR
mRNA in testes and granulosa cells. Should exon 6A be
mutated, the NMD machinery might be unable to process the
transcripts efficiently and, if a substantial part of them is
translated, the functional LHCGR protein will compete with
the truncated LHCGR protein derived from terminal and
internal exon 6A variants [19,20]. Via dimerization of the full-
length LHCGR with the truncated exon 6A variant, this might
result in improper receptor trafficking [21].
Further studies on patients lacking ‘‘classical’’ genetic
Figure 7. The A557C Mutation Abolishes LHCGR Response to hCG
(A) Minigenes were generated by ligating together the LHCGR cDNA
from exons 1–6, the genomic DNA fragment encompassing exon 6 to
exon 7 of the LHCGR gene from a patient carrying the A557C mutation
and one control (wild type), and the LHCGR cDNA from exons 7–11.
(B) The constructs were cloned into the pTarget expression vector and
transiently transfected in COS7 cells. RT-PCR of the region exon 6 to exon
7 revealed the predominant expression of the LHCGR mRNA lacking exon
6A (wt) for the wild-type LHCGR, while the A557C mutation led to
predominant inclusion of exon 6A short and long (A557C). Signal
transduction studies were performed as follows: Transfection efficiency
was monitored by Renilla luciferase activity. Cells were stimulated by hCG
for 3 h and extracellular cAMP was measured by RIA. Results of three
independent experiments (mean 6 SEM) are shown. A significant (p ¼
0.02, Kruskall-Wallis test) dose-dependent increase of cAMP production
was observed in the presence of the wild-type LHCGR minigene, whereas
the response was abolished in the presence of the A557C mutation in
exon 6A (C).
doi:10.1371/journal.pmed.0050088.g007
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alterations in the LHCGR will shed new light on the
pathophysiological role of exon 6A in LH/CG function and
in clinical conditions of LH resistance.
Supporting Information
Figure S1. Exon 6A: Sequence Comparison, Phylogeny, and Genomic
Organization
(A) Upper part: Genomic and cDNA nucleotide sequence comparison
of exon 6A from human (Homo sapiens), chimpanzee (Pan troglodytes),
cynomolgus monkey (Macaca fascicularis), marmoset (Callithrix jacchus),
and lemur (Eulemur coronatus). Identical nucleotides are indicated by
an asterisk. Sequences encompassing internal exon 6A are indicated
by the grey line, while terminal exon 6A is indicated by a black line.
Typical exon elements are given in bold italics or are boxed (poly[A]
signal). Lower part: Comparison of the deduced amino acid sequence
of exon 6A.
(B) Evolutionary pedigree of primate lineage evolution after Singer et
al. (2004). The approximate time of DNA insertion is indicated by the
arrows. Time scale in million of years (mya).
(C) Revised organization of the genomic region between exon 6 and 7 of
the human, cynomolgus monkey, and mouse LHCGR gene. The exonic
size is given above and the intronic size below the genomic elements.
Found at doi:10.1371/journal.pmed.0050088.sg001 (4.6 MB PDF).
Figure S2. Revised Complete Genomic Organization of the Human
LHCGR Gene Now Consisting of 12 Exons
Exon sizes are given above the boxes, intron sizes below.
Found at doi:10.1371/journal.pmed.0050088.sg002 (9 KB PDF).
Figure S3. Immunofluorescence Localization of HA-Tagged LHCGR
Proteins in Transiently Transfected COS7 Cells
(A) HA-tagged, wild-type terminal exon 6A LHCGR.
(B) HA-tagged, A557C terminal exon 6A LHCGR.
(C) Full-length HA-tagged LHCGR protein.
Both truncated LHCGR variants, wild-type and mutated, show a
predominantly intracellular localization (A and B), while the full-
length receptor is localized intracellularly ([C] left) and membrane
bound ([C] right). Immunofluorescence was performed using an HA
antibody (1:200, Santa Cruz) and an anti-mouse IgG-FITC–labeled
secondary antibody (1:64 dilution) and was visualized using either an
inverse epifluorescence microscope (Axioskop II, Zeiss, Germany, [A–
C] left column) or a confocal microscope (Leica TCS-SL, Germany
[A–C] right column). For the confocal analysis the cells were
permeabilized. Bar indicates 50 lM.
Found at doi:10.1371/journal.pmed.0050088.sg003 (173 KB PDF).
Figure S4. Immunohistochemical Localization of the LHCGR in
Human Testes
Leydig cells are positive for LHCGR in normal spermatogenesis (A)
and in the testes of a patient with LCH caused by an F194A
inactivating mutation in LHCGR (see Gromoll J, et al. [2002] Eur J
Endocrinol 147: 597] (B), whereas no LHCGR expression can be
detected in Leydig cells of the A557C patient (C). a-smooth muscle
actin staining was used as positive control for the same patient (D).
Bar indicates 100 lM.
Found at doi:10.1371/journal.pmed.0050088.sg004 (357 KB PDF).
Figure S5. Functional Characterization of the T461I and the G558C
Mutations
(A) Signal transduction hCG-dependent cAMP-responsive luciferase
activity measured in wild-type LHR (filled circle), LHR-T461I mutant
receptor (square), and empty expression plasmid pSG5 (triangles)
expressing HEK293 cells. The hCG response of the mutant LH
receptor is almost completely absent. Renilla, control of transfection
efficiency; RLU, relative luciferase units. Construction of the
expression plasmid pSG5-LHRWT and pSG5-LHR-T461I, culture
and transfection of HEK293 cells, and the determination of cAMP-
dependent luciferase response were performed as described pre-
viously (see Richter-Unruh A, et al. [2004] J Clin Endocrinol Metab 89:
5161).
(B) Sequencing results of the compound heterozygous patient
displaying the exon 6A and exon 11 mutations.
Figure 8. Transcriptional Network of the LHCGR Gene
Hypothetical model of the transcriptional network of the LHCGR gene including the novel exon 6A in the wild type (hollow arrows) or mutated (filled
arrows) forms. The primary transcript of the LHCGR gene includes exon 6A, which can then be skipped in the mature mRNA giving rise to the full-length
LHCGR protein, or is spliced into the terminal or internal exon 6A variants. Since exon 6A contains a stop codon (asterisk), the terminal variant may be
translated into a truncated LHCGR protein, which remains mainly trapped within the cell and could hypothetically interact with the mature, full-length
protein. Conversely, the stop codon in the internal 6A variants is recognized by the NMD pathway, which actively eliminates these transcripts. Under
physiological conditions, both the mature transcript without exon 6A and the terminal 6A variant are present in roughly equal amounts in cells normally
expressing the LHCGR (hollow arrows of equal width). In mutation(s) of exon 6A, the NMD surveillance mechanism is probably inadequate to eliminate
the internal exon 6 variants, which accumulate in the cell and alter the relative abundance of the various transcripts, possibly resulting in an excessive
increase of truncated LHCGR protein, incompatible with ‘‘normal’’ receptor function.
doi:10.1371/journal.pmed.0050088.g008
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(C) TaqMan RT-PCR quantification of internal exon 6 A inclusion in
exon trap experiments using the wild-type or G558C exon 6A
constructs. The expression of internal variants was analyzed after
transfection in COS7 cells and RT-PCR of pSPL3 constructs
containing the wild type (WT) exon 6A (along with 150 bp 59 and
39 of it: see Figure 2) or exon 6A after introduction of the G558C
mutation as described in Figure 4. Densitometric quantification (in
arbitrary units (AU) of internal exon 6A variants RT-PCR results
(both short and long variant together) of two independent experi-
ments. Results are mean 6 standard error of the mean (SEM).
Found at doi:10.1371/journal.pmed.0050088.sg005 (126 KB PDF).
Table S1. Distribution of Exon 6A SNPs in Patients and Controls
Found at doi:10.1371/journal.pmed.0050088.st001 (42 KB DOC).
Accession Numbers
The accession numbers of the items discussed in this paper are:
human LHCGR gene (GeneID 3973; http://www.ncbi.nlm.nih.gov/);
Leydig cell hypoplasia (MIM 152790); and exon 6A clone from M.
mulatta testis (EST database CD766751; http://www.ncbi.nlm.nih.gov/).
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Editors’ Summary
Background. A person’s sex is determined by their complement of X
and Y (sex) chromosomes. Someone who has two X chromosomes is
genetically female and usually has ovaries and female external sex
organs. Someone who has an X and a Y chromosome is genetically male
and has testes and male external sex organs. Sometimes, though, the
development of the reproductive organs proceeds abnormally, resulting
in a person with an ‘‘intersex’’ condition whose chromosomes, gonads
(ovaries or testes), and external sex organs do not correspond. Leydig cell
hypoplasia (LCH; also called male pseudohermaphroditism or a disorder
of sex development) is an XY female intersex condition. People with this
inherited condition develop testes but also have a vagina (which is not
connected to a womb), and they do not develop breasts or have periods.
This mixture of sexual characteristics arises because the Leydig cells in
the testes are underdeveloped. Leydig cells normally secrete testoster-
one, the hormone that promotes the development and maintenance of
male sex characteristics. Before birth, chorionic gonadotropin (CG; a
hormone made by the placenta) stimulates Leydig cell development and
testosterone production; after birth, luteinizing hormone (LH), which is
made by the pituitary gland, stimulates testosterone production. Both
hormones bind to the LH/CG receptor, a protein on the surface of Leydig
cells. In LCH, this receptor either does not bind CG and LH or fails to tell
the Leydig cells to make testosterone.
Why Was This Study Done? The gene that encodes the LH/CG receptor
is called LHCGR. Several mutations (genetic changes) that inactivate the
LC/CG receptor have been identified in people with LCH. However, the
LHCGR gene is apparently normal in 50% of people with this intersex
condition. In this study, the researchers examine the LHCGR gene in
detail to try to find the underlying genetic defect in these individuals.
What Did the Researchers Do and Find? The researchers used several
molecular biology techniques to identify a new exon—exon 6A—within
the human LHCGR gene. (Exons are DNA sequences that contain the
information for making proteins; introns are DNA sequences that
interrupt the coding sequence of a gene. Both introns and exons are
transcribed into messenger RNA [mRNA] and the exons are then
‘‘spliced’’ together to make the mature mRNA, which is translated into
protein.) The researchers identify several differently spliced LHCGR mRNA
transcripts that contain exon 6A—a terminal exon 6A mRNA that
contains exons 1–6 and exon 6A, and two internal exon 6A mRNAs that
also contain exons 7–11. The researchers report that human testes
express high levels of the terminal exon 6A transcript, which is translated
into a short version of LHCGR protein that remains within the cell (full-
length LHCGR moves to the cell surface). By contrast, testes contain low
levels of the internal exon 6A mRNAs. This is because exon 6A contains
two premature stop codons (DNA sequences that mark the end of a
protein), which trigger ‘‘nonsense-mediated decay’’ (NMD), a cellular
surveillance mechanism that regulates protein synthesis by degrading
mRNAs that contain internal stop codons. When the researchers
screened 16 people with LCH but without known mutations in the
LHCGR gene, three had mutations in exon 6A. Laboratory experiments
show that these mutations greatly increased the amounts of the internal
exon 6A transcripts present in cells and interfered with the cells’ normal
response to chorionic gonadotropin.
What Do These Findings Mean? These findings identify a new,
functional exon in the LHCGR gene and show that mutations in this
exon cause some cases of LCH. This is the first time that a human disease
has been associated with mutations in an exon that is a target for NMD.
In addition, these findings provide important insights into how the
LHCGR is regulated. The researchers speculate that a complex network
that involves the exon 6A-containing transcripts and NMD normally
tightly regulates the production of functional LHCGR already at the
transcriptional level. When mutations are present in exon 6A, they
suggest, NMD is the predominant pathway for all the exon 6A-containing
transcripts, thereby drastically decreasing the amount of functional
LHCGR.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050088.
 The MedlinePlus Encyclopedia has a page on intersex conditions (in
English and Spanish)
 Wikipedia has pages on intersexuality and on the LH/CG receptor
(note that Wikipedia is a free online encyclopedia that anyone can
edit; available in several languages)
 The Intersex Society of North America provides information and
support for the parents of children with intersex conditions
 The Androgen Insensitivity Syndrome Support Group also provides
some general information about intersex conditions, including
information about LCH and other XY female conditions (in several
languages)
 Sequence-Structure-Function-Analysis (SSFA), run by a group of
researchers in Germany (Leibniz-Institut fu¨r Molekulare Pharmakologie;
Humboldt-Universita¨tzu Berlin), is a database dealing the sequence,
structure, and function of glycoprotein hormone receptors
 Glycoprotein-hormone Receptors Information System (GRIS), from
Universite´ Libre de Bruxelles and Institut de Recherche Interdiscipli-
naire en Biologie Humaine et Mole´culaire, is a database giving
structural information on the LHCGR
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